GlassScriptPhysician profile
Doris A Best
NPI 1659303014
$443.02
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $13.08 · 2021: $50.97 · 2022: $26.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $127.11 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $51.38 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $39.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.86 | 2019 | |
| Pfizer INC. | $24.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $24.65 | 2019 | |
| Abbvie INC. | $22.33 | 2021 | |
| Theratechnologies INC. | $16.60 | 2019 | |
| Lilly USA, LLC | $14.58 | 2022 | |
| Celgene Corporation | $14.02 | 2019 | |
| Sanofi Pasteur INC. | $12.90 | 2019 | |
| Merck Sharp & Dohme LLC | $12.16 | 2021 | |
| Emd Serono, INC. | $11.67 | 2019 | |
| Strongbridge US INC. | $11.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.